Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2008

01-01-2008 | Clinical Trial Report

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis

Authors: Robert L. Fine, David R. Fogelman, Stephen M. Schreibman, Manisha Desai, William Sherman, James Strauss, Susan Guba, Riolan Andrade, John Chabot

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2008

Login to get access

Abstract

Purpose

We developed a laboratory based regimen called GTX which induces synergistic apoptosis in human pancreatic cancer cells. This retrospective review summarizes our clinical experience with GTX in an initial group of 35 patients; 66% untreated and 34% failed prior therapies.

Methods

All patients treated with GTX for metastatic pancreatic cancer, prior to initiation of a prospective phase II trial of GTX were assessed and followed until death. GTX consisted of capecitabine (X), 750 mg/m2 p.o. BID on days 1–14, gemcitabine (G) (750 mg/m2) over 75 min and docetaxel (T) (30 mg/m2) on days 4 and 11. Thus one cycle of GTX was 14 days with 7 days off for a 21 day cycle. Tumor assessments were repeated every 3 cycles.

Results

All 35 patients had metastatic pancreatic cancer (94% liver, 6% lung sites). Grade 3–4 hematological toxicities were: leukopenia and thrombocytopenia—both 14%, and anemia 9%, respectively. The overall response rate of all 35 patients treated with GTX (from 0.5 cycles onward) was 29% (CR/PR) by WHO criteria, and 31% had a minor response or stable disease (MR, SD). At the metastatic sites for the 35 patients, there were 9% complete (CR) and 31% partial (PR) responses (total 40%). For the 31 patients who had their primary tumor (4 patients had a prior Whipple resection), there were 13% CR and 19% PR for a response rate of 32% at the primary tumor site. Overall median progression free survival of responders was 6.3 months (95% C.I. 4.4–10.4 months) and median survival was 11.2 months (95% C.I. 8.1–15.1 months). Survival after initiation of GTX at 12, 18, 24 and 30 months was 43, 29, 20, and 11%, respectively.

Conclusion

Our retrospective review suggests that GTX has potential as a regimen for untreated and treated metastatic pancreatic cancer.
Literature
1.
2.
Burris HA, Moore MJ, Anderson J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Onc 15(6):2403–2413
3.
Brand R, Capadano M, Tempero M (1997) A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15(4):331–341PubMedCrossRef
4.
Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Onc 21(18):3402–3408CrossRef
5.
Moore M, Goldstein D, Hamm J et al (2005) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol 23:1s, (Suppl, Abstr 1)
6.
Cunningham D, Chau I, Stocken D, Barletta E, Moscetti L, Recchia F et al Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer Suppl 4, Abstr. PS 11
7.
Fine RL, Fogelman DR, Sherman W et al (2003) The GTX regimen: A biochemically synergistic combination for advanced pancreatic cancer (PC). Proc Am Soc Clin Onc Abstr #1129
8.
Fine RL, Fogelman DR, Schreibman S, Guba S, Sharma J, Shapiro G (2004) GTX chemotherapy for metastatic pancreatic cancer: Response, survival, and toxicity data. J Clin Oncol 22:381s suppl. Abstr #4271
9.
Sherman WH, Fine RL (2001) Combination gemcitabine and docetaxel in advanced adenocarcinoma of the pancreas. Oncology 60(4):316–321PubMedCrossRef
10.
Hess V, Salzberg M, Borner M et al (2003) Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: A phase I/II trial. J Clin Oncol 21(1):66–68PubMedCrossRef
11.
Fogelman DR, Sherman W, Schreibman S, Fine RL (2003) Effective salvage chemotherapy with minimal toxicity for relapsed, advanced pancreatic cancer. Proc Am Soc Clin Onc Abstr #1517
12.
Fogelman D, Fine RL, Schreibman S (2004) Effective salvage therapy (T-GX) for pancreatic cancer patients after chemotherapy with GTX. J Clin Oncol 22:380s suppl. Abstr #4268
13.
Khorana A, Fine RL (2004) Pancreatic cancer and thromboembolic disease. Lancet Oncol 5(11):655–663PubMedCrossRef
14.
Poplin E, Levy D, Berlin J et al (2006) Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin(GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 24(18):2006, LBA 4004
15.
Cartwright TH, Cohn A, Varkey JA et al (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20(1):160–164PubMedCrossRef
16.
Stathopoulos GP, Syrigos K, Polyzos A et al (2004) Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol 15:224–229PubMedCrossRef
17.
Hermann R, Bodoky G, Ruhstaller T et al (2005) Gemcitabine (G) plus capecitabine versus G alone in advanced/metastatic pancreatic cancer. A randomized phase III study of the SAKK and CECOG groups, Proc Am Soc Clin Oncol Abst #4010
18.
Rougier P, Adenis A, Dureux M et al (2000) A phase II study: Docetaxel as first line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 36:1016–1025PubMedCrossRef
19.
Androulakis N, Kourousis C, Dimopoulos M (1999) Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II trial. J Clin Oncol 17:1779–1785PubMed
20.
Schneider BP, Ganjoo KN, Seitz DE et al (2003) Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 65(3):218–223PubMedCrossRef
21.
Louvet C et al (2004) Gemcitabine versus GEMOX (gemcitabine + oxaliplatin) in non resectable pancreatic adenocarcinoma : Final results of the GERCOR /GISCAD Intergroup Phase III. J Clin Oncol 22:315s suppl, abstr #4008
22.
Heineman V, Quietzsch D, Gieseler F (2003) A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma, Proc Am Soc Clin Oncol Abst #1003
23.
Rocha Lima CM, Rotche R, Jeffrey M et al (2003) A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc Am Soc Clin Onc Abst #1005
24.
Kozuch P, Grossbard ML, Barzdins A et al (2001) Irinotecan Combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory pancreatic cancer. Oncologist 6(6):488–495PubMedCrossRef
25.
El-Rayes BF, Zalupski MM, Shields AF et al (2003) Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 15(1):2920–2925CrossRef
26.
Araneo M, Bruckner HW, Grossbard ML et al (2003) Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin and cisplatin (GFP): A highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. Cancer Invest 21(4):489–496PubMedCrossRef
27.
28.
Kindler HL, Bylow KA, Hochster HS et al (2006) A randomized phase III study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis. J Clin Onc 24(18S):A4040
29.
Berlin JD, Adak S, Vaughn DJ et al (2000) A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group study (E3296). Oncology 58:215–218PubMedCrossRef
30.
Berlin JD, Catalano P, Thomas J et al (2002) Phase III study of gemcitabine with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270–3275PubMedCrossRef
31.
Reiss H, Helm A, Niedergethmann M et al (2005) Randomized, prospective multicenter phase III trial of gemcitabine, 5FU, folinic acid versus gemcitabine alone in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol Abst #4009
32.
Hidalgo M, Castellano D, Paz-Ares L et al (1999) Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17(2):585–592PubMed
33.
Fine RL, Fogelman DR, Sherman W et al (2006) Gemcitabine, Docetaxel, and Capecitabine (GTX) in the treatment of metastatic pancreatic cancer (PC): A prospective phase II Study. Proc Am Soc Clin Oncol Abst #14024
34.
Sawada N, Ishikawa T, Fukase Y et al (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/docetaxel in human cancer xenografts. Clin Cancer Res Suppl 4(4):1013–1019
35.
Fogelman DR, Chen J, Chabot J, Allendorf J, Schreibman S, Ennis R, Fine RL (2004) The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: From 5-FU to GTX. Surg Oncol Clin No Am 13:711–735CrossRef
Metadata
Title
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis
Authors
Robert L. Fine
David R. Fogelman
Stephen M. Schreibman
Manisha Desai
William Sherman
James Strauss
Susan Guba
Riolan Andrade
John Chabot
Publication date
01-01-2008
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2008
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-007-0473-0

Other articles of this Issue 1/2008

Cancer Chemotherapy and Pharmacology 1/2008 Go to the issue

Original Article

The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer

Original Article

A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus

Original Article

Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer

Original Article

The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers

Original Article

Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring

Original Article

Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits